Bumrungrad Hospital (BH) Stock Overview
Owns and operates hospitals and healthcare centers in Thailand and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 3/6 |
| Future Growth | 2/6 |
| Past Performance | 5/6 |
| Financial Health | 6/6 |
| Dividends | 4/6 |
Rewards
Risk Analysis
No risks detected for BH from our risk checks.
BH Community Fair Values
Create NarrativeSee what 17 others think this stock is worth. Follow their fair value or set your own to get alerts.
Analyst Price Targets
Bumrungrad Hospital Public Company Limited Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | ฿187.50 |
| 52 Week High | ฿214.00 |
| 52 Week Low | ฿136.00 |
| Beta | 0.22 |
| 1 Month Change | -0.27% |
| 3 Month Change | 3.88% |
| 1 Year Change | 11.61% |
| 3 Year Change | -16.29% |
| 5 Year Change | 59.57% |
| Change since IPO | 930.22% |
Recent News & Updates
Narrative Update • Jun 16
BH: Higher Margin Assumptions Will Eventually Fail To Justify Current Premium
Analysts have raised their price target for Bumrungrad Hospital from THB160 to about THB163.66, citing updated assumptions that include adjusted revenue growth, higher profit margin expectations, a slightly lower discount rate, and a modestly lower future P/E multiple. What's in the News No recent news stories, periodicals, or key developments were provided for Bumrungrad Hospital, so current publicly reported catalysts cannot be summarized here.
Narrative Update • Jun 02
BH: Special Dividend And Stable Cash Flow Assumptions Will Support Upside
Analysts have adjusted their price target for Bumrungrad Hospital from THB240 to THB230, reflecting updated views on slightly higher revenue growth and profit margins, together with a lower assumed future P/E multiple. What's in the News No recent company specific news, periodical coverage, or key developments were provided in the available sources for Bumrungrad Hospital.Narrative Update • May 02
BH: Special Dividend And Stable Cash Flow Assumptions Will Support Upside
Analysts are maintaining their THB 240.00 price target for Bumrungrad Hospital, citing only slight adjustments to revenue growth, profit margin, and forward P/E assumptions in their updated model. What's in the News Board meeting set for 18 February 2026 to prepare the agenda for General Meeting of Shareholders No. 33 in 2026 (company filing).
Narrative Update • Apr 18
BH: Dividend Windfall And Share Conversion Will Support Future Upside
Analysts have slightly adjusted their price target for Bumrungrad Hospital to THB201.32 from THB202.14, reflecting minor tweaks to model inputs such as fair value and assumed future P/E, while keeping core assumptions like discount rate, revenue growth, and profit margin broadly consistent. What's in the News The board meeting on 18 February 2026 set the agenda for General Meeting of Shareholders No. 33 in 2026, which will address several corporate matters for Bumrungrad Hospital (company disclosure).Narrative Update • Apr 04
BH: Future Dividend Policy Will Drive Attractive Upside Potential Ahead
Analysts now estimate Bumrungrad Hospital’s fair value at THB202.14, reduced from THB214.62, citing updated assumptions around revenue growth, profit margins, and a lower forward P/E multiple. What's in the News The board meeting on 18 February 2026 set the agenda for the General Meeting of Shareholders No. 33 in 2026, which will consider key corporate matters including dividends and capital structure changes (company disclosures).Recent updates
Narrative Update • Jun 16
BH: Higher Margin Assumptions Will Eventually Fail To Justify Current Premium
Analysts have raised their price target for Bumrungrad Hospital from THB160 to about THB163.66, citing updated assumptions that include adjusted revenue growth, higher profit margin expectations, a slightly lower discount rate, and a modestly lower future P/E multiple. What's in the News No recent news stories, periodicals, or key developments were provided for Bumrungrad Hospital, so current publicly reported catalysts cannot be summarized here.Narrative Update • Jun 02
BH: Special Dividend And Stable Cash Flow Assumptions Will Support Upside
Analysts have adjusted their price target for Bumrungrad Hospital from THB240 to THB230, reflecting updated views on slightly higher revenue growth and profit margins, together with a lower assumed future P/E multiple. What's in the News No recent company specific news, periodical coverage, or key developments were provided in the available sources for Bumrungrad Hospital.Narrative Update • May 02
BH: Special Dividend And Stable Cash Flow Assumptions Will Support Upside
Analysts are maintaining their THB 240.00 price target for Bumrungrad Hospital, citing only slight adjustments to revenue growth, profit margin, and forward P/E assumptions in their updated model. What's in the News Board meeting set for 18 February 2026 to prepare the agenda for General Meeting of Shareholders No. 33 in 2026 (company filing).Narrative Update • Apr 18
BH: Dividend Windfall And Share Conversion Will Support Future Upside
Analysts have slightly adjusted their price target for Bumrungrad Hospital to THB201.32 from THB202.14, reflecting minor tweaks to model inputs such as fair value and assumed future P/E, while keeping core assumptions like discount rate, revenue growth, and profit margin broadly consistent. What's in the News The board meeting on 18 February 2026 set the agenda for General Meeting of Shareholders No. 33 in 2026, which will address several corporate matters for Bumrungrad Hospital (company disclosure).Narrative Update • Apr 04
BH: Future Dividend Policy Will Drive Attractive Upside Potential Ahead
Analysts now estimate Bumrungrad Hospital’s fair value at THB202.14, reduced from THB214.62, citing updated assumptions around revenue growth, profit margins, and a lower forward P/E multiple. What's in the News The board meeting on 18 February 2026 set the agenda for the General Meeting of Shareholders No. 33 in 2026, which will consider key corporate matters including dividends and capital structure changes (company disclosures).Narrative Update • Mar 21
BH: Special Dividend And Stable Assumptions Will Support An Undervalued Outlook
Analysts maintain the THB 240.00 price target for Bumrungrad Hospital, citing broadly consistent assumptions on long term revenue growth, profit margin, discount rate, and future P/E that keep their overall valuation view unchanged. What's in the News The General Meeting on 22 April 2026 is set to consider a remaining dividend for 2025 of THB 9 per share, totaling THB 7,162 million.Narrative Update • Mar 06
BH: Special Dividend And Stable Assumptions Will Sustain An Undervalued Outlook
Analysts have kept their price target for Bumrungrad Hospital steady at THB240, reflecting only very small adjustments to assumptions around revenue growth, profit margin, and future P/E expectations. What's in the News Proposed remaining 2025 dividend of THB 9 per share, split between a year-end dividend of THB 3 per share and a special dividend of THB 6 per share, for a total payout of THB 7,162m, subject to shareholder approval at the General Meeting on 22 April 2026 (Key Developments).Narrative Update • Feb 20
BH: Adjusted Margins And Multiple Will Still Support An Undervalued Outlook
Analysts have trimmed their fair value estimate for Bumrungrad Hospital from THB 276.22 to THB 240.00, reflecting updated assumptions that combine a slightly higher revenue growth outlook with lower profit margin expectations and a modestly lower future P/E multiple. Valuation Changes Fair Value: THB 276.22 trimmed to THB 240.00, a moderate reduction in the central value estimate.Narrative Update • Feb 06
BH: Slightly Softer Assumptions Will Support A Still Undervalued Outlook
Narrative Update on Bumrungrad Hospital Analysts have made only a marginal upward adjustment to their fair value estimate for Bumrungrad Hospital, to roughly ฿276.22 from about ฿276.16. This reflects slightly updated assumptions around discount rate, revenue growth, profit margin and future P/E.Narrative Update • Jan 20
BH: Stronger Margins And Stable Assumptions Will Support An Undervalued Outlook
Analysts have lifted their price target for Bumrungrad Hospital to approximately ฿276 from around ฿269, citing updated assumptions that reflect slightly higher revenue growth, a modestly stronger profit margin, and a small adjustment in the projected future P/E multiple. Valuation Changes Fair Value Estimate moved from about ฿269.20 to around ฿276.16, a small upward adjustment in the implied valuation.Narrative Update • Jan 05
BH: Higher Profitability Assumptions Will Support An Undervalued Outlook
Analysts have nudged their price target for Bumrungrad Hospital slightly higher to reflect small adjustments in fair value, discount rate, revenue growth, profit margin assumptions, and a lower future P/E multiple. Valuation Changes Fair Value: Adjusted slightly from THB 268.97 to THB 269.20, indicating only a minor change in the model outcome.Narrative Update • Dec 14
BH: Future Revenue Outlook Will Offset Slight Margin Compression And Maintain Fair Value
Analysts have raised their price target for Bumrungrad Hospital from THB 152 to THB 160, reflecting expectations of faster revenue growth and a higher justified future P E multiple, despite slightly lower forecast profit margins and a marginally higher discount rate. Valuation Changes Fair Value: Raised slightly from THB 152.0 to THB 160.0, implying a modest uplift in the target price.Narrative Update • Nov 13
BH: Revenue Outlook Will Drive Attractive Upside Potential Ahead
Bumrungrad Hospital Price Target Raised on Growth Outlook Analysts have increased their fair value estimate for Bumrungrad Hospital from 209.86 THB to 214.62 THB, citing improved revenue growth projections. This comes despite a slightly higher discount rate and lower profit margin expectations.Narrative Update • Aug 07
New Cancer Center And Robotic Surgery Will Expand Global Capacity
The top metrics for Bumrungrad Hospital—future P/E and consensus revenue growth—remained essentially flat, supporting a marginal increase in the analyst price target to THB209.00. Valuation Changes Summary of Valuation Changes for Bumrungrad Hospital The Consensus Analyst Price Target remained effectively unchanged, moving only marginally from THB208.48 to THB209.00.
New Narrative • Dec 12
Facility Expansion And Genomic Medicine Investments Set To Drive Robust Revenue Growth
Expansion and investment in advanced facilities and genomic medicine are set to attract patients, boosting future revenue growth.Shareholder Returns
| BH | TH Healthcare | TH Market | |
|---|---|---|---|
| 7D | 4.7% | 0.1% | -2.6% |
| 1Y | 11.6% | -7.9% | 29.7% |
Return vs Industry: BH exceeded the TH Healthcare industry which returned -7.9% over the past year.
Return vs Market: BH underperformed the TH Market which returned 29.7% over the past year.
Price Volatility
| BH volatility | |
|---|---|
| BH Average Weekly Movement | 3.0% |
| Healthcare Industry Average Movement | 3.4% |
| Market Average Movement | 4.1% |
| 10% most volatile stocks in TH Market | 10.2% |
| 10% least volatile stocks in TH Market | 1.9% |
Stable Share Price: BH has not had significant price volatility in the past 3 months compared to the TH market.
Volatility Over Time: BH's weekly volatility (3%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1975 | n/a | Artirat Charukitpipat | www.bumrungrad.com |
Bumrungrad Hospital Public Company Limited owns and operates hospitals and healthcare centers in Thailand and internationally. It offers services in the areas of allergy, arrhythmia, behavioural health, breast, home, heart valve, robotic surgery, rehabilitation, spine, pediatrics, colorectal surgery, complex coronary artery intervention, comprehensive sleep, cornea transplant, dental, diagnostic, dialysis, radiology and nuclear medicine, digestive disease, ear, nose, throat, emergency, endocrinology, esperance, diabetes, expatriate liaison, eye, fertility, gastrointestinal motility, health screening, holistic wound care, horizon regional cancer, hyperbaric oxygen therapy, nephrology, neuroscience, orthopaedics, perinatal, plastic surgery, pulmonary, refractive surgery, memory, robotic scoliosis, skin, sports medicine and joint, surgery, travel medicine, urology, scientific wellness, skin and aesthetic, and women's centers. The company also operates breastfeeding, Yangon, COVID-19 recovery, IVF, hearing and balance, medical, new life healthy aging, Parkinson's disease and movement disorders, pride, surgery, and vaccine clinics and centers.
Bumrungrad Hospital Public Company Limited Fundamentals Summary
| BH fundamental statistics | |
|---|---|
| Market cap | ฿148.26b |
| Earnings (TTM) | ฿7.57b |
| Revenue (TTM) | ฿25.49b |
19.7x
P/E Ratio5.8x
P/S RatioIs BH overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| BH income statement (TTM) | |
|---|---|
| Revenue | ฿25.49b |
| Cost of Revenue | ฿12.13b |
| Gross Profit | ฿13.36b |
| Other Expenses | ฿5.79b |
| Earnings | ฿7.57b |
Last Reported Earnings
Mar 31, 2026
Next Earnings Date
Aug 14, 2026
| Earnings per share (EPS) | 9.52 |
| Gross Margin | 52.40% |
| Net Profit Margin | 29.69% |
| Debt/Equity Ratio | 0.07% |
How did BH perform over the long term?
See historical performance and comparisonDividends
2.7%
Current Dividend Yield53%
Payout RatioCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/07/31 11:35 |
| End of Day Share Price | 2026/07/31 00:00 |
| Earnings | 2026/03/31 |
| Annual Earnings | 2025/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Bumrungrad Hospital Public Company Limited is covered by 42 analysts. 21 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Angus Mackintosh | Aletheia Analyst Network Limited |
| Kawee Manitsupavong | Asia Plus Securities Company Limited |
| Laura Emmet Carney | Bernstein |